HomeExamplesDataDocumentationLoginBook a demo
HomeExamplesDataDocumentationLoginBook a demo

SEED Therapeutics

Ownership
Private
Employees
~17
Therapeutic Areas
OncologyNeurologyInfectious Diseases
Stage
Other
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Molecular GluesTargeted Protein Degradation (TPD)

SEED Therapeutics General Information

SEED Therapeutics has achieved multiple milestones in its research collaborations, including a 3rd milestone with Lilly R&D in March 2024 and a strategic research collaboration with Eisai in August 2024. The company plans to advance its oral RBM39 Degrader into Phase 1 testing in 2025 and progress its Tau degrader program for Alzheimer's disease into in vivo efficacy in 2025, with IND planned for 2026.

Contact Information

Website
https://seedtherapeutics.com/
Primary Industry
Biotech
Corporate Office
New York, New York
United States

Drug Pipeline

RBM39 degrader
IND
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to SEED Therapeutics's pipeline data

Book a demo

Key Partnerships

Eli Lilly and Company, Eisai Co., Ltd.

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

SEED Therapeutics Funding

Deal TypeDateAmountStatusStage
InvestmentMar 25, 2026$30.0MCompletedOther
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view SEED Therapeutics's complete valuation and funding history, request access »

SEED Therapeutics Financial Metrics

See full profile
Book a demo
OverviewDrug PipelineTechnologiesPartnershipsFundingCompetitorsAnalysisPatentsLicensing Deals